8-K: IMAC Holdings Seeks Stockholder Approval for Potential Stock Issuance and Faces Nasdaq Delisting Appeal

IMAC Holdings files a proxy statement seeking stockholder approval for potential stock issuances and an amendment to increase authorized common stock, while also appealing a Nasdaq delisting determination.

Summary

• IMAC Holdings, Inc. filed a definitive proxy statement on February 11, 2025, seeking stockholder approval for several key proposals.
• These proposals include the potential issuance of over 19.99% of the company's outstanding common stock under the Series G Preferred Stock and related warrants, as well as under the Committed Equity Financing.
• The company is also seeking approval for an amendment to its Certificate of Incorporation to increase the total number of authorized common stock shares.
• The company's former independent accounting firms have provided their consents in connection with the proxy statement filing.
• A special meeting will be held on March 26, 2025, for stockholders to vote on these proposals.
• IMAC Holdings is also appealing a Nasdaq delisting determination due to non-compliance with the Minimum Equity Rule.
• A hearing is scheduled for March 4, 2025, and the company's common stock will continue to trade on Nasdaq during the appeal process.

Sentiment

Score: 4

Explanation: The document presents both positive and negative aspects. The company is actively seeking financing and appealing the delisting, but the delisting notice and potential dilution of shares are concerning.

Positives

• The company is taking steps to address its non-compliance with Nasdaq listing requirements by appealing the delisting determination.
• The company is proactively seeking stockholder approval for potential financing options.

Negatives

• The company received a notice from Nasdaq regarding non-compliance with the Minimum Equity Rule.
• The company is facing potential delisting from Nasdaq.

Risks

• Failure to obtain stockholder approval for the proposed stock issuances and amendment could limit the company's financing options.
• The company may not be successful in its appeal of the Nasdaq delisting determination, which could negatively impact its stock price and investor confidence.
• Continued non-compliance with Nasdaq listing requirements could lead to delisting.

Future Outlook

The company's future depends on the outcome of the stockholder vote on the proposed stock issuances and the Nasdaq delisting appeal.

Industry Context

Many small-cap companies face challenges in maintaining Nasdaq listing compliance, especially those in volatile sectors or undergoing significant strategic changes. Seeking stockholder approval for increased share issuance is a common strategy for companies needing capital, but it can dilute existing shareholders' equity.

Comparison to Industry Standards

• Many companies facing Nasdaq delisting issues attempt to regain compliance through various measures, including reverse stock splits, raising additional capital, or demonstrating improved financial performance.
• Other companies in similar situations include those in the biotechnology and pharmaceutical sectors, which often rely on equity financing to fund research and development.
• Comparable companies that have faced delisting challenges include those with low market capitalization and negative equity.

Stakeholder Impact

• Shareholders face potential dilution if the proposed stock issuances are approved.
• Employees' job security could be affected by the company's financial stability and Nasdaq listing status.
• The company's ability to meet its obligations to suppliers and creditors could be impacted by its financial performance and access to capital.

Next Steps

• Stockholders will vote on the proposed stock issuances and amendment at the special meeting on March 26, 2025.
• The company will attend a hearing on March 4, 2025, to appeal the Nasdaq delisting determination.

Key Dates